A real life retrospective analysis of drug expenditure reveals no significant cost difference between infliximab and adalimumab in the treatment of Adult Crohn's Disease

  1. Lookup NU author(s)
  2. Dr Christopher Lamb
  3. Maria Price
  4. Dr John Mansfield
Author(s)Lamb CA, Price M, Robinson M, Gunn MC, Thompson NP, Mansfield JC
Publication type Conference Proceedings (inc. Abstract)
Conference NameAnnual Meeting of the British Society of Gastroenterology
Conference LocationBirmingham, England
Year of Conference2011
Date14-17 March 2011
Volume60 (Suppl. 1)
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
PublisherGut: BMJ Publishing Group
Actions    Link to this publication
Library holdingsSearch Newcastle University Library for this item